MedTrace Logo

Evaluation of Bacillus Subtilis R0179 in Healthy Young Adults

NCT01802151 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2015-12-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effect of three doses of the probiotic B. subtilis (Bacillus subtilis R0179) delivered in capsules on gastrointestinal and general wellness in healthy young adults, survival through the gastrointestinal tract and impact on intestinal microbes.

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

B. subtilis R0179

B. subtilis R0179 for a period of 4 weeks. One capsule per day.

DIETARY_SUPPLEMENT

Placebo

Placebo (starch, magnesium stearate, citric acid) capsules for a period of 4 weeks. One capsule per day.

Sponsors & Collaborators

  • Lallemand Human Nutrition

    collaborator UNKNOWN

  • University of Florida

    lead OTHER

Principal Investigators

  • Wendy J Dahl, PhD, RD · University of Florida

  • Bobbi Henken-Langkamp, PhD, RD · University of Florida

  • Volker Mai, PhD · University of Florida

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01802151 on ClinicalTrials.gov